Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2: A Retrospective Review of 31 Patients

@article{Plotkin2012BevacizumabFP,
  title={Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2: A Retrospective Review of 31 Patients},
  author={Scott R. Plotkin and Vanessa Leigh Merker and Chris F Halpin and Dominique Jennings and Michael J. McKenna and Gordon J. Harris and Fred G. II Barker},
  journal={Otology \& Neurotology},
  year={2012},
  volume={33},
  pages={1046–1052}
}
Objective Early studies suggest that bevacizumab treatment can result in tumor shrinkage and hearing improvement for some patients with neurofibromatosis type 2 (NF2). The aim of this study was to report extended follow-up in a larger cohort of similarly treated patients. Study Design Retrospective study. Setting Tertiary referral center Patients Thirty-one consecutive NF2 patients who received bevacizumab for progressive vestibular schwannomas. Main Outcome Measure Hearing improvement, defined… Expand
Natural History of Vestibular Schwannoma Growth and Hearing Decline in Newly Diagnosed Neurofibromatosis Type 2 Patients
TLDR
These data provide potentially useful information for the design of clinical trials for NF2 vestibular schwannoma. Expand
Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2
TLDR
It is likely that a better functional outcome would be expected if targeted therapies were discussed early in the management of the disease, and thorough multidisciplinary evaluation is necessary to identify the best candidates prior to treatment. Expand
Long-Term Effects of Bevacizumab on Vestibular Schwannoma Volume in Neurofibromatosis Type 2 Patients.
TLDR
Bevacizumab may reduce tumor growth rate and the risk of progression based on both volumetric and linear measurements. Expand
Bevacizumab for Hearing Preservation in Neurofibromatosis Type 2: Emphasis on Patient-Reported Outcomes and Toxicities
  • Pavlina Sverak, M. Adams, +6 authors C. Moertel
  • Medicine
  • Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • 2019
TLDR
Bvacizumab treatment was followed by hearing improvement in 56% of patients, while decreased tumor volume was noted in 47%. Expand
Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients
TLDR
Bvacizumab appears to be a useful therapeutic choice in NF2 cases to control the growth of VS, and a randomised control trial is necessary to prove this assumption. Expand
Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation.
TLDR
Treatment with bevacizumab in this large, UK-wide cohort decreased VS growth rates and improved hearing and quality of life and the potential risk of surgical iatrogenic damage was reduced due to an associated reduction in VS surgical rates. Expand
Minimal Effect of Bevacizumab Treatment on Residual Vestibular Schwannomas after Partial Resection in Young Neurofibromatosis Type 2 Patients
TLDR
The comprehensive follow-up on 16 VS in nine NF2 patients did show heterogenous effects of bevacizumab on small residual vestibular schwannomas after surgery both regarding tumor size and hearing preservation, and smaller and slower growing tumor residuals seem to behave differently to bev ACIZumab than reported for not-operated faster growing VS. Expand
The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2.
TLDR
Bvacizumab treatment in NF2 patients with spinal cord ependymomas results in a decreases in the size of intratumoral and juxtatumoral cysts as well as adjacent-cord syringes and a decrease in cord edema. Expand
The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2
TLDR
Bvacizumab improved hearing and reduced the size of VS in some patients with progressive NF2 which corroborates previous findings; however, the risk of severe side effects should be carefully considered and discussed with the patients prior to treatment. Expand
Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients
TLDR
It is suggested that a minority of NF2-associated meningiomas shrink during bevacizumab therapy and that these responses were of short duration. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients
TLDR
Because a subset of patients experienced prolonged stable disease, time-to-progression may be more appropriate than radiographic or hearing response for anti-EGFR agents in NF2-associated VS. Expand
Vestibular Schwannoma Growth Rates in Neurofibromatosis Type 2 Natural History Consortium Subjects
  • W. Slattery, L. Fisher, Z. Iqbal, Mark Oppenhiemer
  • Medicine
  • Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • 2004
TLDR
Slightly greater than 1 in 10 diagnosed NF2-related vestibular schwannomas increased in size by at least 5 mm by 4 years of follow-up, if still untreated at that time. Expand
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
TLDR
VEGF blockade with bevacizumab improved hearing in some, but not all, patients with neurofibromatosis type 2 and was associated with a reduction in the volume of most growing vestibular schwannomas. Expand
Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation.
TLDR
It is demonstrated that radiographic regression of VS can be sustained under continuous bevacizumab application and that dose reduction is possible, as the tumors will gradually return to their original size upon drug discontinuation. Expand
Hearing Changes after Diagnosis in Neurofibromatosis Type 2
Objective: Describe the changes in hearing ability and progression of disease over time in subjects with neurofibromatosis Type 2 enrolled in a multicenter natural history study of vestibularExpand
Concordance of Bilateral Vestibular Schwannoma Growth and Hearing Changes in Neurofibromatosis 2: Neurofibromatosis 2 Natural History Consortium
  • L. Fisher, J. Doherty, M. Lev, W. Slattery
  • Medicine
  • Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • 2009
TLDR
Clinically, tumor change or hearing deterioration on one VS cannot be used to predict changes in the other VS, which suggests that, although NF2 is a Mendelian disease, the germline genotype-phenotype relationship may resemble that of complex disorders. Expand
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma
TLDR
This work identifies research goals in NF2 to facilitate future trial conduct, and identifies the expectations for time to tumor progression and time to measurable hearing loss in untreated NF2-related VS, and the relation of both endpoints to patient prognostic factors. Expand
Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.
TLDR
Two cases are reported which confirm that bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, causes regression of vestibular schwannomas in patients with a previous history of gamma knife radiosurgery or failed treatment with another form of vascular endothelium growth factor targeted therapy. Expand
Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II.
OBJECTIVE Vestibular schwannomas (VS) are common, benign, VIIIth cranial nerve tumors. Treatment in patients with the genetic disorder neurofibromatosis type II (NF2) is complicated by theirExpand
Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
TLDR
Treatment with bevacizumab induced regression of progressive vestibular schwannomas by more than 40% and substantially improved hearing in the patient treated for 6 months, and may provide an effective treatment for progressive Vestibular Schwannoma in patients with NF2. Expand
...
1
2
3
4
...